Categories AlphaGraphs, Earnings, Retail
Macy’s first quarter results beat expectations; lifts outlook
Shares of Macy’s Inc. (M) were up 9% during the pre-market trading after it reported upbeat results for the first quarter and raised the outlook for the year. Macy’s stock, which jumped about 27% so far this year, spiked 7% when the market opened today. Net sales increased 3.6% to $5.54 billion compared to last year. Comparable sales on an owned basis were up 3.9% while comp sales on an owned plus licensed basis were up 4.2%.
Net income attributable to shareholders was $139 million or $0.45 per share compared to $78 million or $0.26 per share in the prior-year period. Adjusted diluted EPS was $0.48.
Macy’s Q1 2018 Earnings Infographics
The Cincinnati-based retailer said the results exceeded its expectations and performance was strong across all brands and geographical regions. Inventory is in a stable position while physical stores along with the ecommerce and digital channels continue to perform well. Macy’s digital business grew in the double-digits during the quarter.
Macy’s decided to end its JV with Fung Retailing Limited in China but will continue to operate on TMall and other social media platforms.
The company, which battles with retail giants like Amazon (AMZN) and Walmart (WMT), lifted its guidance for the fiscal year 2018. Currently, adjusted EPS is targeted to be $3.75 to $3.95 compared with the previous guided range of $3.55 to $3.75. Total sales are expected to range from a 1% decline to a 0.5% increase in 2018. Comparable sales on an owned plus licensed basis are expected to increase 1-2%.
Despite the solid results, Macy’s is not safe from the Amazon effect, and neither are its peers. Macy’s is undertaking several initiatives to tackle this competition including focusing on Macy’s Backstage. The company’s acquisition of concept store Story is part of these efforts.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on